The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.
 
Neeta Somaiah
Consulting or Advisory Role - Bayer; Bayer; Blueprint Medicines; Deciphera; Immune Design
Research Funding - MedImmune
 
Anthony Paul Conley
Consulting or Advisory Role - Bayer; Deciphera; Deciphera; Genentech; Guidepoint Global; Medscape; Nektar; Novartis
Research Funding - Bavarian Nordic; Ignyta; Iovance Biotherapeutics (Inst); MedImmune (Inst)
Travel, Accommodations, Expenses - Genentech
 
Heather Y. Lin
No Relationships to Disclose
 
Behrang Amini
No Relationships to Disclose
 
Sharjeel H Sabir
No Relationships to Disclose
 
Dejka M. Araujo
No Relationships to Disclose
 
Robert S. Benjamin
Stock and Other Ownership Interests - Express Scripts (I); Gilead Sciences (I); Johnson & Johnson (I); Merck Serono (I); Pfizer (I)
 
J Andrew Livingston
No Relationships to Disclose
 
Shreyaskumar Patel
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Daiichi Sankyo; Epizyme; Immune Design; Janssen; Lilly; MaxiVax ; Novartis
Research Funding - Blueprint Medicines (Inst)
 
Ravin Ratan
Stock and Other Ownership Interests - Johnson & Johnson (I)
Consulting or Advisory Role - Epizyme
Research Funding - Epizyme; SpringWorks Therapeutics
 
Vinod Ravi
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Novartis
Patents, Royalties, Other Intellectual Property - Author Royalties from Uptodate
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Maria Alejandra Zarzour
No Relationships to Disclose
 
Wei-Lien Wang
No Relationships to Disclose
 
Taylor Tate
No Relationships to Disclose
 
Christina Lynn Roland
Research Funding - Bristol-Myers Squibb
 
Najat C. Daw
Consulting or Advisory Role - Bayer; Incyte
 
Andrew Futreal
No Relationships to Disclose
 
Alexander J. Lazar
Leadership - Archer; Iterion Therapeutics; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb; Deciphera; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - AstraZeneca/MedImmune; Asuragen; Bayer; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; Merck; MSD Oncology; OncoCyte; Pfizer
Speakers' Bureau - MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Adaptive Biotechnologies (Inst); Akoya Biosciences (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); OncoPlex Diagnostics (Inst); Pfizer (Inst); Silicon Biosytems (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; MSD Oncology; Pfizer
 
Patrick Hwu
Stock and Other Ownership Interests - Dragonfly Therapeutics; Immatics
Consulting or Advisory Role - Dragonfly Therapeutics; GlaxoSmithKline; Immatics; Sanofi
Research Funding - Genentech (Inst)